Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

The 2026 R&D agenda includes approximately 20 planned pivotal study starts, 8 key data readouts, and 4 regulatory decisions.

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on ...

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York ...

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 ...

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...